Diarrhea News and Research

Latest Diarrhea News and Research

Sanofi Aventis receives FDA approval for Aubagio to treat relapsing forms of MS

The U.S. Food and Drug Administration today approved Aubagio (teriflunomide), a once-a-day tablet for the treatment of adults with relapsing forms of multiple sclerosis (MS).

13 Sep 2012

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has approved AUBAGIO (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

13 Sep 2012

MHRA approves Sucampo’s AMITIZA to treat chronic idiopathic constipation in the U.K.

Sucampo Pharmaceuticals, Inc. today announced that it has received approval from the Medicines and Healthcare products Regulatory Agency for AMITIZA (lubiprostone) 24 mcg twice daily for the treatment of chronic idiopathic constipation (CIC) and associated symptoms in adults, when response to diet and other non-pharmacological measures (e.g., educational measures, physical activity) are inappropriate.

12 Sep 2012

Gene therapy regimen can safely restore immune systems to children with Bubble Boy disease

UCLA stem cell researchers have found that a gene therapy regimen can safely restore immune systems to children with so-called "Bubble Boy" disease, a life threatening condition that if left untreated can be fatal within one to two years.

12 Sep 2012

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Santarus, Inc. today announced that its Phase III clinical study to evaluate the safety and efficacy of the investigational drug, rifamycin SV MMX, met the primary endpoint of reducing time to last unformed stool (TLUS) in patients with travelers' diarrhea.

12 Sep 2012

Most Asian countries fail to include rotavirus vaccine in national immunization programs citing cost as barrier

"Most countries in Asia have yet to make the rotavirus vaccine part of their national immunization program (NIP), despite a World Health Organization (WHO) recommendation to do so," IRIN reports.

11 Sep 2012

Simple low-cost biosensor to detect contaminated drinking water

Diarrheal disease is the second leading cause of death in children under five years old - killing as many as 1.5 million children worldwide every year. These startling statistics from the World Health Organization (2009) point to the reason why a group of undergraduate students from Arizona State University is working to develop a low-cost biosensor - a simple device that would detect contaminated drinking water.

7 Sep 2012

Constipation drug may bring US patients relief

The US Food and Drug Administration has approved linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in adults.

6 Sep 2012

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

Antibiotics are medicines used to treat infections or diseases caused by bacteria, such as some respiratory tract infections (including pneumonia and whooping cough), urinary tract infections, skin infections and infected wounds.

6 Sep 2012

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

AMAG Pharmaceuticals, Inc. today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization in Switzerland for ferumoxytol, an intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

6 Sep 2012

FDA continues review of Salix’s Crofelemer new drug application

Napo Pharmaceuticals, Inc. was informed today that the Food and Drug Administration is continuing its review of the new drug application seeking approval of crofelemer for the treatment of chronic diarrhea in people living with HIV/AIDS on anti-retroviral therapy.

6 Sep 2012

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).

6 Sep 2012

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved BOSULIF (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

6 Sep 2012

FDA approves Bosulif to treat chronic myelogenous leukemia

The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.

5 Sep 2012

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

Avanir Pharmaceuticals, Inc. today announced the enrollment of the first patient in study AVR-131. The study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.

5 Sep 2012

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

The US Food and Drug Administration has approved a higher dose of Exelon Patch (rivastigmine transdermal system) for the treatment of people with mild to moderate Alzheimer's disease.

4 Sep 2012

Astellas Pharma receives FDA approval for Xtandi to treat metastatic CRPC

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

1 Sep 2012

FDA approves Ironwood’s LINZESS to treat irritable bowel syndrome with constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. announced today that LINZESS (linaclotide) was approved by the U.S. Food and Drug Administration (FDA) as a once-daily treatment for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

31 Aug 2012

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Bayer HealthCare and Onyx Pharmaceuticals today announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral multi-kinase inhibitor regorafenib for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients whose disease has progressed despite prior treatment.

31 Aug 2012

Ironwood receives FDA approval for Linzess to treat chronic idiopathic constipation, IBS

The U.S. Food and Drug Administration today approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults.

31 Aug 2012

Diarrhea News and Research

Latest Diarrhea News and Research

Sanofi Aventis receives FDA approval for Aubagio to treat relapsing forms of MS

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

MHRA approves Sucampo’s AMITIZA to treat chronic idiopathic constipation in the U.K.

Gene therapy regimen can safely restore immune systems to children with Bubble Boy disease

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Most Asian countries fail to include rotavirus vaccine in national immunization programs citing cost as barrier

Simple low-cost biosensor to detect contaminated drinking water

Constipation drug may bring US patients relief

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

FDA continues review of Salix’s Crofelemer new drug application

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

FDA approves Bosulif to treat chronic myelogenous leukemia

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

Astellas Pharma receives FDA approval for Xtandi to treat metastatic CRPC

FDA approves Ironwood’s LINZESS to treat irritable bowel syndrome with constipation

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Ironwood receives FDA approval for Linzess to treat chronic idiopathic constipation, IBS

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in